ALQA:NSD-Alliqua BioMedical, Inc (USD)

COMMON STOCK | Other | NSD

Last Closing Price

USD 1.35

Change

0.00 (0.00)%

Market Cap

USD 2.24M

Volume

3.80K

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Alliqua BioMedical, Inc. develops, manufactures, and markets high water content, electron beam cross-linked, and aqueous polymer hydrogels or gels used in wound care, medical diagnostics, transdermal drug delivery, and cosmetics in the United States. It also provides contract manufacturing services to the OEM market. The company is headquartered in Langhorne, Pennsylvania.

Company Website : http://www.alliqua.com

Address : 1010 Stony Hill Road, Suite 200 19067,Yardley,USA

Employees : 6

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 1.85

52 Week High : 1.49

52 Week Low : 1.26

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-12-04 )

Largest Industry Peers for Other

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
LGCY Legacy Reserves Inc

N/A

 USD61,525,874.67B 1.10 5.30
FTD FTD Companies, Inc

N/A

 USD28,725,913.80B N/A N/A
KEYW The KeyW Holding Corporation

N/A

 USD24,651,104.38B 166.80 24.48
SNHY Helios Technologies, Inc

N/A

 USD17,848,852.22B 1,000,000.00 N/A
QTNA Quantenna Communications, Inc

N/A

 USD8,997,243.52B 175.07 79.98
INSY INSYS Therapeutics, Inc

N/A

 USD4,995,459.82B 115.90 N/A
CHKE Apex Global Brands Inc

N/A

 USD384,202.91B 17.30 N/A
AMCN AirNet Technology Inc

N/A

 USD308,457.30B 1.00 N/A
PDVW pdvWireless, Inc

N/A

 USD95,944.74B N/A N/A
AIPT Predictive Oncology Inc

N/A

 USD38,513.36B N/A N/A

ETFs Containing ALQA

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Other)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -49.75% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -49.75% N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain -49.75% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -49.75% N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain -94.49% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -94.49% N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -27.89% N/A N/A 6% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -27.89% N/A N/A 6% F
Risk Return Profile  
Volatility (Standard Deviation) 40.24% N/A N/A 31% F
Risk Adjusted Return -69.30% N/A N/A 9% F
Market Capitalization 2.24M N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Other)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio N/A N/A N/A N/A N/A
Price / Cash Flow Ratio -0.23 N/A N/A N/A N/A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital -30.39% N/A N/A N/A N/A
Return on Assets N/A N/A N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 1.85 N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.